This corporate presentation by Caladrius Biosciences provides an overview of the company and its pipeline. Key points include: - Caladrius has two technology platforms using CD34+ cells for ischemic repair and T regulatory cells for immune modulation. - They have a late-stage development pipeline including programs in critical limb ischemia (CLBS12), coronary microvascular dysfunction (CLBS14-CMD), and refractory angina (CLBS14-RfA). - The presentation highlights clinical data from prior studies of CD34+ cell therapy and outlines ongoing and planned trials across the pipeline.

1. Corporate Presentation
David J. Mazzo, PhD
President and Chief Executive Officer
October 2018 | NASDAQ: CLBS

2. Forward-looking statements advisory
This Investor Presentation contains forward-looking statements within the meaning of Private
Securities Litigation Reform Act of 1995. Forward-looking statements reflect management’s
current expectations, as of the date of this presentation, and involve certain risks and
uncertainties. All statements other than statements of historical fact contained in this Investor
Presentation are forward-looking statements. The Company’s actual results could differ
materially from those anticipated in these forward-looking statements as a result of various
factors. Factors that could cause future results to differ materially from the recent results or
those projected in forward-looking statements include the “Risk Factors” described in the
Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission
(“SEC”) on March 22, 2018, as subsequently amended on April 2, 2018, and and in the
Company’s other periodic filings with the SEC. The Company’s further development is highly
dependent on, among other things, future medical and research developments and market
acceptance, which are outside of its control. You are cautioned not to place undue reliance on
forward-looking statements, which speak only as of the date of this Investor Presentation.
Caladrius does not intend, and disclaims any obligation, to update or revise any forward-
looking information contained in this Investor Presentation or with respect to the matters
described herein.
2

3. Caladrius Biosciences: Uniquely positioned for near-term success
 Late-stage therapeutics development company with 2 technology platforms
 CD34+ cells for ischemic repair (CLBS12, CLBS14-CMD, CLBS14-RfA)
 T regulatory cells for immune modulation (CLBS03)
 Financially stable and debt-free
 Strong balance sheet (~$50 million cash as of June 30, 2018)
 Low operating cash burn (~$5 million/quarter)
 Multiple value creating events within the next 18 months
 Key regulatory and data milestones across the pipeline
3

4. Experienced executive team with broad domain-specific expertise
David J. Mazzo, PhD
President and Chief Executive Officer
30+ years of experience in all aspects of large pharma (Merck, Baxter, RPR, HMR,
Schering-Plough) and emerging biopharma (Chugai USA, Regado) company
operations; successful international drug development across all therapeutic areas and
international capital raising and business transactions; Chairman of EyePoint Pharma
Douglas W. Losordo, MD
Executive VP, Global Head of R&D and
Chief Medical Officer
25+ years of experience as a leader in cell therapy research and development;
renowned clinician with noteworthy academic (Tufts, Northwestern, NYU) and industry
(Baxter) credentials; pioneer of CD34+ cell therapy
Joseph Talamo, CPA, MBA
Senior VP and Chief Financial Officer
25+ years of experience as a versatile finance executive with strong accounting/audit
background (KPMG) and leadership roles in publicly traded pharmaceutical
development and commercial-stage companies (OSI Pharmaceuticals, Bristol-Myers
Squibb)
Todd Girolamo, JD, MBA
Senior VP, General Counsel and
Corporate Secretary
25+ years of legal experience as a practicing attorney (Cahill, Gordon & Reindel; Reid
& Priest) as well as finance and biotechnology industry experience (Oppenheimer,
CIBC, Leerink Swann)
John D. Menditto
Executive Director
Investor Relations and Corporate Communications
20+ years of experience as an investor relations and corporate communications
professional with a major focus on healthcare and life science (Novartis, Medco Health
Solutions, Argos Therapeutics)
4

5. Ischemic Repair
Autologous CD34+ cells
5

6. CD34+ cells promote angiogenesis of the microvasculature
 >700 subjects studied in randomized double-blind placebo-controlled trials
provide consistent evidence of therapeutic benefit and tolerance
 Improved mortality, reduced chest pain and increased exercise tolerance in refractory angina1
 Reduced amputation in critical limb ischemia2
 Improved function in claudication3
6
1. Losordo et al. Circ Res 2011.; Povsic et al. JACC Cardiovasc Interv. 2016.
2. Losordo et al. Circ Cardiovasc Interv 2012.
3. From US study (n=17); Not yet published
Normal microvasculature Augmented microvasculature
post-CD34+ cells introduction
Compromised microvasculature

7. Simple, scalable and economical autologous cell therapy process
7
Cells returned to
same patient
Maximum of 4 days from donation to injection
Day 1: Sample collection via apheresis; shipment to processing center
Day 2: CD34+ cells isolated, prepared for patient and shipment to clinic
Day 3-4: Cells returned to patient through intracoronary infusion or intramuscular
injection near impacted area, depending on indication
Isolation of
CD34+ Cells
Sample collection
ShipmentShipment

8. CLBS12
Critical Limb Ischemia (CLI)
8

9. 9
Week 4 Post-treatment Week 12 Post-treatmentBeforeTreatment
Provided by Dr. Atsu Kawamoto
CD34+ cell therapy improves blood flow in ischemic limbs
CLI Patient Laser Doppler Scans:

10. 10
CLI Represents a Multi-billion Dollar Global Market Opportunity
Japan USA Europe*
No-option CLI patients eligible for CLBS12
(not eligible for revascularization)
11,000 1,496,000 1,330,000
CLI represents an expedited commercial opportunity in Japan
*Europe:
Source: The Sage Group
Source: National Institute of Health
Source: CIA World Factbook; Norgren et al. (2007) J Vasc Surg
Source: CIA World Factbook; Becker F, et al. (2011), Chapter I: definitions, epidemiology, clinical presentation and prognosis
Source: Norgren et al., (2007) J Vasc Surg
 CLBS12 eligible for early conditional approval based on current phase 2 study
 Estimated >$100M initial commercial opportunity with significant pharmaco-eco benefits
 Successful outcome in Japan could lead to expedited development in other major markets

11. 11
Design • Prospective, open label, controlled, randomized trial (1:1 w/SOC) CLI patients
Primary Endpoint • Time to continuous CLI-free status (2 consecutive monthly visits, adjudicated independently)
Study Size • 30 patients with no-option CLI plus 5 patients with Buerger’s Disease; ~10 centers in Japan
Dose • Up to 106 autologous G-CSF-mobilized peripheral blood-derived CD34+ cells/kg per affected limb
Control/ comparator
• Standard of Care drugs approved in Japan (e.g., antiplatelets, anticoagulants and vasodilators)
• Choice of pharmacotherapy will be made by the investigators according to protocol
Mode of
administration • Intramuscular, 20 injections in affected lower limb in single administration
Timing/Cost
• First patient enrolled in December 2017 with final results expected early 2020
• ~$7 million costs remain to study completion (fully funded)
CLBS12 pivotal phase 2 study in Japan
Awarded SAKIGAKE (“breakthrough”) designation with priority review
Eligible for early conditional approval

12. CLBS14-CMD
Coronary Microvascular Dysfunction (CMD)
12

13. 13
CMD is an unmet medical need with significant market potential
1Cleveland Clinic/AHA (American Heart Association)
2Townsend, N, et al.: Cardiovascular disease in Europe: epidemiological update 2016, European Heart Journal, Volume 37, Issue 42, 7 November 2016, Pages 3232–3245
3Kita, T; Coronary heart disease risk in Japan – an East/West divide?, European Heart Journal Supplements, Volume 6, Issue suppl_A, 1 March 2004, Pages A8–A11
4Ueshima, H, et al.; Cardiovascular Disease and Risk Factors in Asia, AHA Journal, December 16/23, 2008, Volume 118, Issue 25
 Nearly 50% of patients with Coronary Artery Disease (CAD) have CMD
 Multi-billion dollar global opportunity based on significant pharmaco-eco benefits
USA1 Europe2 Japan3,4
~8,300,000 ~6,000,000 ~1,000,000
CMD Patients Eligible for CLBS14-CMD
Europe:

14. CLBS14-CMD Phase 1b/2a proof-of-concept study (ESCaPE-CMD)
Currently enrolling patients in USA
14
Design • Interventional, open label, proof-of-concept trial
Primary Endpoint • Safety and the evaluation of adverse events
Secondary Endpoints
• Changes from baseline to 6 months for coronary flow reserve, endothelial-dependent
microvascular function, time to angina; other cardiovascular metrics
Study Size • 20 patients at 2 centers in the USA (Cedars Sinai, LA & Mayo Clinic)
Dose • Up to 300 x 106 CD34+ cells
Control • No control arm
Mode of administration • Single intracoronary infusion
Timing/Cost
• First patient enrolled April 2018 with final results expected by end of 2019
• NIH grant covers majority of costs (CLBS to contribute ~$0.7 million – fully funded)

15. CLBS14-RfA
Refractory Angina (RfA)
15

16. RfA Patients Eligible for CLBS14-RfA
1Global Cardiology Science & Practice: April 30, 2015
2National Institutes of Health: 2009
3Heart and Metabolism: 2017
4European Heart Journal (Kaplan Meier Analysis)
5Extrapolated from percentage of chronic heart failure patient prevalence in US and Europe
CLBS14-RfA presents a multi-billion dollar global market opportunity
16
Europe:
USA123 Europe3 Japan5
~900K ~1.0M ~200K
 Patients with RfA often have multiple costly comorbidities

17. US development program in Refractory Angina (CLBS14-RfA)
Statistically Positive Late Stage Clinical Program Data Exclusively Licensed from Shire
 Phases 1, 2, & 3 clinical studies1,2,3 (combined n=304); patient-level pooled-analysis results show
improvement in total exercise time (TET), angina frequency and major cardiac events (MACE)
(European Heart Journal, 1/2018)
17
1 Losordo, D.W., et al, Intramyocardial transplantation of autologous CD34+++ stem cells for intractable angina: a phase I/Iia double-blind, randomized controlled trial. Circluation, 2007. 115(25): p. 3165-3172
2 Losordo, D.W., et al., Intramyocardial, autologous CD34+++ cell therapy for refractory angina. Circ Res, 2011. 109(4): p. 428-36.
3 Povsic, T.J., et al., The RENEW Trial: Efficacy and Safety of Intramyocardial Autologous CD34++(+) Cell Administration in Patients With Refractory Angina. JACC Cardiovasc Interv, 2016. 9(15): p. 1576-85.
IMPROVED total exercise time throughout the 3–
12 month period on treadmill stress test
Significant DECREASE in all-cause mortality at
24 months
LOWER relative frequency of angina throughout
the 3–12 month period

18. Total exercise time (TET) and angina frequency results
US development program in Refractory Angina (CLBS14-RfA)
Statistically Positive Late Stage Clinical Program Data Exclusively Licensed from Shire
 Phases 1, 2, & 3 clinical studies1,2,3 (combined n=304); patient-level pooled-analysis results show
improvement in total exercise time (TET), angina frequency and major cardiac events (MACE)
(European Heart Journal, 1/2018)
18
1 Losordo, D.W., et al, Intramyocardial transplantation of autologous CD34+++ stem cells for intractable angina: a phase I/Iia double-blind, randomized controlled trial. Circluation, 2007. 115(25): p. 3165-3172
2 Losordo, D.W., et al., Intramyocardial, autologous CD34+++ cell therapy for refractory angina. Circ Res, 2011. 109(4): p. 428-36.
3 Povsic, T.J., et al., The RENEW Trial: Efficacy and Safety of Intramyocardial Autologous CD34++(+) Cell Administration in Patients With Refractory Angina. JACC Cardiovasc Interv, 2016. 9(15): p. 1576-85.
Auto-CD34+ Cells Placebo

19. Major cardiac events (MACE) results
US development program in Refractory Angina (CLBS14-RfA)
Statistically Positive Late Stage Clinical Program Data Exclusively Licensed from Shire
 Phases 1, 2, & 3 clinical studies1,2,3 (combined n=304); patient-level pooled-analysis results show
improvement in total exercise time (TET), angina frequency and major cardiac events (MACE)
(European Heart Journal, 1/2018)
19
1 Losordo, D.W., et al, Intramyocardial transplantation of autologous CD34+++ stem cells for intractable angina: a phase I/Iia double-blind, randomized controlled trial. Circluation, 2007. 115(25): p. 3165-3172
2 Losordo, D.W., et al., Intramyocardial, autologous CD34+++ cell therapy for refractory angina. Circ Res, 2011. 109(4): p. 428-36.
3 Povsic, T.J., et al., The RENEW Trial: Efficacy and Safety of Intramyocardial Autologous CD34++(+) Cell Administration in Patients With Refractory Angina. JACC Cardiovasc Interv, 2016. 9(15): p. 1576-85.

20. US development program in Refractory Angina (CLBS14-RfA)
Statistically Positive Late Stage Clinical Program Data Exclusively Licensed from Shire
 IND reactivated with CLBS as sponsor
 RMAT (Regen Medicine Advanced Therapy) designation – awarded 2Q2018
 Granted by the FDA for therapies intended to treat serious conditions
 Therapy must show preliminary evidence of addressing unmet medical need
 Similar to breakthrough therapy designation, it includes increased agency meeting
opportunities and potential for accelerated approval
 FDA meeting to finalize development plan to BLA planned for 4Q2018
 Preliminary discussions indicate grant funding likely to contribute to
any remaining clinical studies
20

21. Immune Modulation
Autologous, ex vivo expanded & activated polyclonal T regulatory cells
CLBS03
21

22. T regulatory cells (Tregs) control immune balance and function
 Deficiency in number or function of Tregs manifests as autoimmune disease
 Augmentation of Tregs is intended to restore the immune system to its “native” state
and reduce/eliminate autoimmune disease symptoms and progression
22
1 Normal immune system:
immune balance
2 Autoimmunity:
immune imbalance
3 Infusion of Tregs:
Immune balance restored
T regulatory cells T effector cells Natural polyclonal T regulatory cells

23. Immune modulation critical to curtailing disease progression and to acceptance
of transplantation or regeneration therapies
23
Chronic blood glucose
management
Disease Modification
(CLBS03)
Function regeneration
Approach
Symptom management
Reduce or eliminate
disease progression;
potentially “curative”
Replace depleted cells/organs
producing insulin; does not
address underlying autoimmune
disease
Insulin
Impact
Improve therapeutic
effect and/or efficiency of
delivery of insulin/analogs
Avoid or reduce need
for insulin by preserving
active beta cells
Provides new source of inslulin
producing cells
Availability Currently available with
more in development
Currently in
Phase 2 trial
Many years of
development remaining

24. 24
USA4 Europe5 Japan6
New onset T1D patients eligible for CLBS03 19,000 54,500 3,000
T1D is a >$1 billion worldwide market opportunity
5Europe:
 Each year ~20,000 newly diagnosed patients <20 years of age in USA1
 3% CAGR worldwide2
 No curative treatments, only lifelong insulin therapy
 Frequent serious, costly co-morbidities
 Preserving remaining beta cell function should slow/stop disease progression
 Leading to long-term pharmaco-economic benefits3
1. National Diabetes Statistic Report, 2014
2. Maahs DM, et al. Endocrinol Metab Clin North Am. 2010
3. Nathan DM, et al. Arch Intern Med. 2009
4. Thunander M et al, Diabetes Res Clin Pract. 2008:82:247-255
5. Haller MJ et al, Pediatr Clin North Am. 2005;52:1553-157
6. Kawasaki E., Matsuura N., Eguchi K., Diabetologia, 2006:49(5):828-36

25. Reliable, scalable & economically viable autologous cell therapy process
 Proprietary and efficient clinical manufacturing process:
 Simple, minimally intrusive cell collection process (whole blood or, eventually, apheresis)
 Reliable and well-characterized cGMP process
 High Phase 2 manufacturing success rate (>93%)
 Discounted development and manufacturing services rates from HCATS through 2024
1 Day 1: Patient whole
blood donation
3 Day ~14: Infusion of Treg
therapy to same patient
Collection & Shipment Processing & Return Shipment Infusion
2 Days 2-13: Treg isolation,
activation & expansion
25

26. CLBS03: Recent onset Type 1 Diabetes program overview
 International regulatory recognition
 FDA Fast Track designation (first time granted to a T1D program) and Orphan designation
 EU ATMP (Advanced Therapeutic Medicinal Product) classification
 Enrollment completed for landmark Phase 2 clinical study in T1D (T-Rex trial)
 T-rex trial based on published clinical studies showing the T regulatory cell therapy is well
tolerated1,2, durable1 and preserving of beta cell function in children2
 CIRM and JDRF grants of ~$10 million combine to offset study costs
 Strategic collaboration with Sanford Research (Sioux Falls, SD) providing $5 million in equity
investment plus operating support for trial and clinical sites
 Planned interim analysis completed: therapy is well tolerated and non-futile for therapeutic effect
 Primary endpoint analysis expected in early 2019
26
1. Bluestone, et al. Science Translational Medicine 2015
2. Marek-Trzonkowska, N et al. Clinical Immunology 2014
3. Remission Definition: Daily dose of insulin ≤ 0.5 UI/kg body weight & fasting c-peptide > 0.5 ng/ml at 12 months after recruitment

27. Phase 2 (T-rex) trial in adolescents with T1D initiated in March 2016
27
Design
• Double-blind, placebo-controlled, randomized (1:1:1) trial
• Adolescent patients ages 8 to <18 with recent-onset T1D (diagnosed within 100 days)
Standard Endpoints
• Preservation of C-peptide level, insulin use, severe hypoglycemic episodes, glucose
and hemoglobin A1c levels
Study Size • 110 patients enrolled across 15 study sites in the USA (enrollment completed in Dec. 2017)
Power • 80% power to detect a 0.2 pmol/mL difference in AUC mean C-peptide (active vs. placebo)
Dose • CLBS03 dose cohorts of 2.5 or 20 million cells/kg body weight
Control • Placebo (standard of care including insulin)
Mode of Administration • Single infusion
Timing/Cost
• Top-line data in early 2019
• <$2 million in study costs remaining (fully funded)

28. Country: USA
Pre-Clinical Phase 1 Phase 2 Phase 3
Country: Japan
Multi-product pipeline based on proprietary technology platforms
28
Active trial
Development plan to
BLA pending FDA
meeting in 4Q18
CLBS14-CMD Coronary Microvascular Dysfunction
CD34+ Cell Therapy Platform
(Ischemic Repair)
T Regulatory Cell Therapy Platform
(Immune Modulation)
CLBS12 Critical Limb Ischemia *
CLBS03 Recent Onset Type 1 Diabetes
CLBS14-RfA Refractory Angina Country: USA
*Eligible for early conditional approval
Country: USA

29. Program 2018 (Jul-Dec) 2019 2020
Key dates and upcoming potential value creating events
29
CLBS03-----------------------------------------------------------------------------------------------------------------------------------------
CLBS12-----------------------------------------------------------------------------------------------------------------------------------------
CLBS14-CMD---------------------------------------------------------------------------------------------------------------------------------
CLBS14-RfA----------------------------------------------------------------------------------------------------------------------------------
Topline Data Expected
Topline Data Expected
Topline Data Expected
FDA Meeting

30. CLBS key financial information1
30
Current Cash2: $50.3m
2018 Actual (Jan-Jun) Operating Cash Burn3: $12.2m
2018 Projected (Jul-Dec) Operating Cash Burn4: $10m
Cash Runway Based on Current Plan4: 2020
Long-Term Debt: $0
Common Shares Outstanding: 9.7m shares
Options Outstanding:
Options Outstanding with Exercise Price < $5.00 = 551,000 shares
Options Outstanding with Exercise Price < $25.00 = 200,000 shares
Options Outstanding with Exercise Price > $25.00 = 393,000 shares
1.1m shares
(average exercise price $33.50)
1 As of June 30, 2018
2 Cash, cash equivalents and marketable securities
3 Includes approximately $2m in final retention payments related to the PCT sales transaction of 2017
4 Excludes CLBS14-RfA development costs - to be determined

31. Caladrius Biosciences: Uniquely positioned for near-term success
 Late-stage therapeutics development company with 2 technology platforms
 CD34+ cells for ischemic repair (CLBS12, CLBS14-CMD, CLBS14-RfA)
 T regulatory cells for immune modulation (CLBS03)
 Financially stable and debt-free
 Strong balance sheet (~$50 million cash as of June 30, 2018)
 Low operating cash burn (~$5 million/quarter)
 Multiple value creating events within the next 18 months
 Key regulatory and data milestones across the pipeline
31

32. Investor Relations Contact
John D. Menditto
Phone: 908.842.0084
Email: jmenditto@caladrius.com
www.caladrius.com
32
NASDAQ: CLBS